Onward® medical reports half year 2024 results and provides a business update

This press release contains inside information within the meaning of article 7(1) of the european market abuse regulation (596/2014) up-lift study results published in nature medicine de novo application submitted to fda to obtain clearance to market the investigational arc-ex ® system in the united states up to eur 52.5m in growth financing obtained from us-based runway growth capital several additional milestones achieved with the investigational arc-bci ™ system, leveraging brain-computer interface (bci) technology to restore thought-driven movement eindhoven, the netherlands, sept. 10, 2024 (globe newswire) -- onward medical n.v.
ARC Ratings Summary
ARC Quant Ranking